Cytokine gene polymorphisms are associated with response to blinatumomab in B‐cell acute lymphoblastic leukemia

Nikeshan Jeyakumar(Stanford Blood Center), Ryotaro Nakamura(City Of Hope National Medical Center), Anthony S. Stein(University of Hohenheim), Vinod Pullarkat(City of Hope), Joo Y. Song(City Of Hope National Medical Center), Sally Mokhtari(City of Hope), Stephen J. Forman(City Of Hope National Medical Center), Ibrahim Aldoss(City of Hope), Guido Marcucci(City of Hope), Samer K. Khaled, Dongyun Yang(City of Hope), Ketevan Gendzekhadze(City Of Hope National Medical Center), Wei Chen(First Affiliated Hospital of Xi'an Jiaotong University), Joycelynne Palmer(City of Hope), Margaret O’Donnell(City Of Hope National Medical Center), Xiwei Wu(City Of Hope National Medical Center)
European Journal Of Haematology
March 15, 2021
10.1111/ejh.13622
Cited by 5

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k